|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Ocular Therapeutix, Inc (OCUL) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
155,920,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ocular Therapeutix is a biopharmaceutical company. Co. commercializes two products in the U.S.: DEXTENZA®, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Co. also has product candidates in preclinical and clinical development designed to utilize its bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,000 |
10,000 |
10,000 |
2,485,812 |
| Total Buy Value |
$69,600 |
$69,600 |
$69,600 |
$12,094,363 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
1 |
1 |
1 |
4 |
| Total Shares Sold |
42,940 |
89,800 |
140,851 |
254,235 |
| Total Sell Value |
$320,320 |
$658,755 |
$1,118,934 |
$1,696,386 |
| Total People Sold |
5 |
6 |
6 |
10 |
| Total Sell Transactions |
5 |
11 |
17 |
30 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Saroj Namrata |
Chief Business OfficerOfficer |
• – – |
2025-06-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
200,000 |
|
- |
|
| Meyers Steve Lawrence |
Chief Commercial OfficerOffice |
• – – |
2025-06-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
152,728 |
|
- |
|
| Raines Merilee |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
46,933 |
|
- |
|
| Hong Seung Suh |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
46,933 |
|
- |
|
| Warden Charles M |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
86,464 |
|
- |
|
| Lindstrom Richard L Md |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
143,145 |
|
- |
|
| Williams Leslie J. |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
51,433 |
|
- |
|
| Graves Adrienne L |
Director |
– • – |
2025-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
14,000 |
50,000 |
|
- |
|
| Waheed Nadia |
Chief Medical Officer |
• – – |
2025-06-02 |
4 |
S |
$8.05 |
$111,581 |
D/D |
(13,861) |
206,805 |
|
- |
|
| Dugel Pravin |
See Remarks |
• • – |
2025-05-23 |
4 |
S |
$7.18 |
$152,352 |
D/D |
(21,219) |
3,499,099 |
|
- |
|
| Heier Jeffrey S. |
Chief Scientific Officer |
• – – |
2025-05-23 |
4 |
S |
$7.18 |
$21,712 |
D/D |
(3,024) |
262,974 |
|
- |
|
| Nayak Sanjay |
Chief Strategy Officer |
• – – |
2025-05-23 |
4 |
S |
$7.17 |
$13,351 |
D/D |
(1,862) |
281,623 |
|
- |
|
| Kaiser Peter |
Chief Development Officer |
• – – |
2025-05-23 |
4 |
S |
$7.17 |
$21,324 |
D/D |
(2,974) |
207,104 |
|
- |
|
| Lindstrom Richard L Md |
Director |
– • – |
2025-05-08 |
4 |
B |
$6.96 |
$69,600 |
D/D |
10,000 |
172,704 |
2.39 |
- |
|
| Kaiser Peter |
Chief Development Officer |
• – – |
2025-02-24 |
4 |
S |
$6.87 |
$20,672 |
D/D |
(3,009) |
210,078 |
|
- |
|
| Heier Jeffrey S. |
Chief Scientific Officer |
• – – |
2025-02-24 |
4 |
S |
$6.87 |
$21,029 |
D/D |
(3,061) |
265,998 |
|
- |
|
| Nayak Sanjay |
Chief Strategy Officer |
• – – |
2025-02-24 |
4 |
S |
$6.84 |
$12,962 |
D/D |
(1,895) |
283,485 |
|
- |
|
| Dugel Pravin |
See Remarks |
• • – |
2025-02-24 |
4 |
S |
$6.87 |
$147,533 |
D/D |
(21,475) |
3,520,318 |
|
- |
|
| Dugel Pravin |
See Remarks |
• • – |
2025-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750,000 |
3,541,793 |
|
- |
|
| Nayak Sanjay |
Chief Strategy Officer |
• – – |
2025-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
111,000 |
285,380 |
|
- |
|
| Notman Donald |
See Remarks |
• – – |
2025-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
115,000 |
308,444 |
|
- |
|
| Waheed Nadia |
Chief Medical Officer |
• – – |
2025-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
79,000 |
220,666 |
|
- |
|
| Notman Donald |
See Remarks |
• – – |
2025-02-04 |
4 |
S |
$7.81 |
$86,839 |
D/D |
(11,119) |
193,444 |
|
- |
|
| Notman Donald |
See Remarks |
• – – |
2025-01-31 |
4 |
S |
$7.84 |
$49,400 |
D/D |
(6,301) |
204,563 |
|
- |
|
| Dugel Pravin |
See Remarks |
• • – |
2024-11-25 |
4 |
S |
$9.01 |
$186,327 |
D/D |
(20,680) |
791,793 |
|
- |
|
174 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
